Search

Your search keyword '"Guillaume Bataillon"' showing total 102 results

Search Constraints

Start Over You searched for: Author "Guillaume Bataillon" Remove constraint Author: "Guillaume Bataillon"
102 results on '"Guillaume Bataillon"'

Search Results

1. Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

2. The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features

3. Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies

4. A catalog of numerical centrosome defects in epithelial ovarian cancers

5. Prediction of Treatment Response in Triple Negative Breast Cancer From Whole Slide Images

6. Can AI predict epithelial lesion categories via automated analysis of cervical biopsies: The TissueNet challenge?

7. HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports

8. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers

9. Hyperechoic breast images: all that glitters is not gold!

13. Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

14. Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer

15. APCgermline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?

16. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

17. FIGURE 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

18. Figure S15 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

19. FIGURE 4 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

20. FIGURE 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

21. Supplementary Table 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

22. FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

23. Supplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

24. Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

26. Le premier data challenge organisé par la Société Française de Pathologie : une compétition internationale en 2020, un outil de recherche en intelligence artificielle pour l’avenir ?

27. Abstract PD11-04: A multi-feature AI-based solution for cancer diagnosis in breast biopsies: A prospective blinded multi-site clinical study

28. Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer

30. 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial

31. 2022-RA-205-ESGO Circulating HPV DNA in cervical cancer: a marker for early detection of relapse

33. 2022-RA-1387-ESGO Patients with minimal residual disease at upfront debulking surgery have similar survival outcome than patients with complete cytorreduction after neoadjuvant chemotherapy

34. Microsatellite instability detection in breast cancer using drop-off droplet digital PCR

35. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study

36. Deep Learning identifies new morphological patterns of Homologous Recombination Deficiency in luminal breast cancers from whole slide images

37. Greedy clustering of count data through a mixture of multinomial PCA

39. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network

40. Neural network for the prediction of treatment response in Triple Negative Breast Cancer *

41. Abstract PD9-05: Stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients

42. Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer

43. Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images

44. Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants

45. Efficacy of Lorlatinib in Primary Crizotinib-Resistant Adult Neuroblastoma Harboring ALK Y1278S Mutation

46. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

47. Abstract P4-15-02: TILs variations, proliferative response and PEPI scores in patients with luminal breast cancer receiving neoadjuvant letrozole-palbociclib or chemotherapy: An extended analysis of the NEOPAL trial

48. [The first data challenge of the french society of pathology: An international competition in 2020, a research tool in A.I. for the future?]

49. Clinical management of atypical ductal hyperplasia on vacuum-assisted biopsy of microcalcifications: External validation study of a decision tree selecting patients eligible for surveillance

50. PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy

Catalog

Books, media, physical & digital resources